Literature DB >> 19344405

CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK.

Julius G Juarez1, Marilyn Thien, Aileen Dela Pena, Rana Baraz, Kenneth F Bradstock, Linda J Bendall.   

Abstract

The mechanisms regulating the migration of leukaemic cells between the blood and bone marrow compartments remain obscure, but are of fundamental importance for the dissemination of the disease. This study investigated the in vivo homing of human B cell progenitor acute lymphoblastic leukaemia (ALL) cells to the femoral bone marrow of non-obese diabetic severe combined immunodeficient (NOD/SCID) mice. It was demonstrated that patient ALL cells use the chemokine axis, chemokine (CXC motif) receptor 4 (CXCR4)/ chemokine (CXC motif) ligand 12 (CXCL12), to home to the femoral marrow. CXCL12-mediated signalling through p38 mitogen-activated protein kinase (MAPK) was required for optimal homing. In contrast, the homing of normal peripheral blood CD34(+) cells and the cytokine-dependent CD34(+) cell line Mo7e was independent of p38MAPK, consistent with the dependence of these cells, as well as normal CD34(+) CD19(+) B cell progenitors, on PI-3K/AKT signalling. Altogether, our data provide clarification of the direct role of CXCL12 in the bone marrow homing of ALL cells and demonstrate unique signalling molecule usage that may have therapeutic implications for this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344405     DOI: 10.1111/j.1365-2141.2009.07648.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Cellular elements of the subarachnoid space promote ALL survival during chemotherapy.

Authors:  Stephen M Akers; Stephanie L Rellick; James E Fortney; Laura F Gibson
Journal:  Leuk Res       Date:  2011-01-26       Impact factor: 3.156

2.  Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Authors:  Lyndsay V Rhodes; Sarah P Short; Nicole F Neel; Virgilio A Salvo; Yun Zhu; Steven Elliott; Yongkun Wei; Dihua Yu; Menghong Sun; Shannon E Muir; Juan P Fonseca; Melyssa R Bratton; Chris Segar; Syreeta L Tilghman; Tammy Sobolik-Delmaire; Linda W Horton; Snjezana Zaja-Milatovic; Bridgette M Collins-Burow; Scott Wadsworth; Barbara S Beckman; Charles E Wood; Suzanne A Fuqua; Kenneth P Nephew; Paul Dent; Rebecca A Worthylake; Tyler J Curiel; Mien-Chie Hung; Ann Richmond; Matthew E Burow
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

3.  Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

Authors:  A Alsadeq; S Strube; S Krause; M Carlet; I Jeremias; C Vokuhl; S Loges; J A Aguirre-Ghiso; A Trauzold; G Cario; M Stanulla; M Schrappe; D M Schewe
Journal:  Leukemia       Date:  2015-06-24       Impact factor: 11.528

4.  The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.

Authors:  Philip Saunders; Adam Cisterne; Jocelyn Weiss; Kenneth F Bradstock; Linda J Bendall
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

Review 5.  CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.

Authors:  Aparecida de Lourdes Perim; Marla Karine Amarante; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Cell Mol Life Sci       Date:  2015-01-09       Impact factor: 9.261

Review 6.  Role of CXCR4 in the progression and therapy of acute leukaemia.

Authors:  Long Su; Zheng Hu; Yong-Guang Yang
Journal:  Cell Prolif       Date:  2021-05-29       Impact factor: 6.831

7.  5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.

Authors:  F V Castro; O J McGinn; S Krishnan; G Marinov; J Li; A J Rutkowski; E Elkord; D J Burt; M Holland; R Vaghjiani; A Gallego; V Saha; P L Stern
Journal:  Leukemia       Date:  2012-01-23       Impact factor: 11.528

8.  Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.

Authors:  R Parameswaran; M Yu; M Lim; J Groffen; N Heisterkamp
Journal:  Leukemia       Date:  2011-04-12       Impact factor: 11.528

9.  Bone Marrow Cells in Acute Lymphoblastic Leukemia Create a Proinflammatory Microenvironment Influencing Normal Hematopoietic Differentiation Fates.

Authors:  Armando Vilchis-Ordoñez; Adriana Contreras-Quiroz; Eduardo Vadillo; Elisa Dorantes-Acosta; Alfonso Reyes-López; Henry Martin Quintela-Nuñez del Prado; Jorge Venegas-Vázquez; Hector Mayani; Vianney Ortiz-Navarrete; Briceida López-Martínez; Rosana Pelayo
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

10.  Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer.

Authors:  Tinghua Hu; Yu Yao; Shuo Yu; Hui Guo; Lili Han; Wenjuan Wang; Tao Tian; Yibin Hao; Zhiyan Liu; Kejun Nan; Shuhong Wang
Journal:  J Biomed Res       Date:  2013-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.